San Diego, CA, United States of America

Rachel T Nishimura

USPTO Granted Patents = 18 

 

 

Average Co-Inventor Count = 12.3

ph-index = 4

Forward Citations = 105(Granted Patents)


Company Filing History:


Years Active: 2015-2024

Loading Chart...
Loading Chart...
Loading Chart...
18 patents (USPTO):

Title: The Innovative Journey of Rachel T. Nishimura: A Patent Leader in Pharmaceutical Development

Introduction: Rachel T. Nishimura, based in San Diego, California, is an accomplished inventor with a remarkable portfolio of 18 patents. Her work primarily focuses on the intersection of molecular biology and pharmacology, particularly in developing innovative therapeutic solutions.

Latest Patents: Among her notable contributions are her latest patents concerning inhibitors of the KEAP1-Nrf2 protein-protein interaction. These patents encompass sultam compounds and pharmaceutical compositions that offer methods for treating various disease states, including inflammatory bowel disease, Crohn's disease, and ulcerative colitis. Rachel's research is pivotal in creating new avenues for treatment options for these complex conditions.

Career Highlights: Rachel T. Nishimura currently contributes her expertise at Janssen Pharmaceutica NV, where she leverages her deep understanding of biochemistry and pharmacology to drive innovation in therapeutic development. Her dedication to scientific research and innovation has solidified her as a prominent figure in her field.

Collaborations: Throughout her career, Rachel has collaborated with notable colleagues such as David A. Kummer and Kevin Douglas Kreutter. These partnerships have not only enriched her work but also helped propel advancements in pharmaceutical research and product development.

Conclusion: Rachel T. Nishimura's contributions to science and medicine underscore the vital role of inventors in improving healthcare. Through her patents and collaborations, Rachel continues to make a significant impact, paving the way for innovative treatments and therapies that benefit patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…